Skip to Content
Merck
CN

Key Documents

View All Documentation

EHU063941

MISSION® esiRNA

targeting human FHL2

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.51
UNSPSC Code:
41105324
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

TCCTCACAGAGAGGGACGACATCCTGTGCCCCGACTGTGGGAAAGACATCTGAATTCAACACAGAGAAGTTGCTGCTTGTGATCTCACACACAGATTTTTATGTTTTCTTTCTCACCCAGGCAATCTTGCCTTCTGGTTTCTTCCAGCCACATTGAGACTTTCTTCTAGTGCTTTTCAGTGATACTCACGTTTGCTTAAACCCTTTAGTGCTTTGTGATAGTTCAGTCCCAGGGAAAGAGAAAACTCGCCCTAGGCCCTAGGTGGGAAGATGGTTTGAAATTTTTGTAATCGAGTAAGGCACACCCAAATGTAAAAATCCTTTTGAATGATGCCTTTATAAATCTTTCTCTCACTGTCTATTTAAGTGCAATTAACATATGTCACGAACTTGAAAGTTTTCTAAACTCAATAAGGTAATGACCAGTTGTTATTTACAGCTCTGTAACCTCCCGTTGCGTCAAGTCTAAACC

Ensembl | human accession no.

ENSG00000115641

NCBI accession no.

NM_001450

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... FHL2(2274)

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Szu-Yuan Li et al.
Scientific reports, 9(1), 6693-6693 (2019-05-02)
RAAS inhibition has been the standard treatment for CKD for years because it can reduce proteinuria and hence retard renal function decline, but the proteinuria reduction effect is still insufficient in many patients. Podocyte foot process and slit diaphragm are
Xuejing Jin et al.
Gene, 669, 99-106 (2018-05-26)
Increasing evidence demonstrates that the four and a half LIM domain (FHL) gene and its protein products have different functions in the progression of various malignancies. However, the role of FHL protein 2 (FHL2) in cervical cancer (CC) has not

Global Trade Item Number

SKUGTIN
EHU063941-50UG04061828381647
EHU063941-20UG04061831351248